Ten million dollars, Samsung, and shiitake mushrooms: The making of Figure 1’s Series B round

The mission of Figure 1 is to democratize medical knowledge. With our newly closed Series B fundraising round, we now have another US$10M and the expertise of such investors as Samsung NEXT and John Hancock/Manulife to further that goal. Simply put, we are here to help healthcare professionals use their shared expertise to improve patient outcomes.

What does that mean, exactly?

The money we have raised will help us bring cases like these to more healthcare professionals in more places around the world. And it’s cases like these that brought a new group of leading investors to our mission-driven company. That’s because these cases, and thousands more like them, illustrate the tremendous power of Figure 1 to:

  • Connect specialists around the world;
  • Identify rare conditions immediately;
  • Help healthcare professionals toward their diagnoses, and;
  • Teach the doctors of tomorrow with real medicine in real time.

Our Series B round is led by Kensington Capital Partners and includes Samsung NEXT, John Hancock/Manulife Financial, Hedgewood, and WTI. In addition to funding, these investors bring deep expertise to the table: Samsung is a global leader in both personal and medical technology, while John Hancock/Manulife offers insurance to more than 22 million customers. They join our existing investors Union Square Ventures, Version One Ventures, and Rho Canada Ventures, who all participated in this round.

With this new investment, Figure 1 will expand our knowledge network, adding to the millions of healthcare professionals who help each other provide better care. We’ll build on our case intelligence, finding new ways to extract value from the tens of thousands of real medical cases in our library. And we’ll continue to do this via a free platform, available to every healthcare professional, at any time of day and no matter where they practice.


Want to know more? Email us at communications@figure1.com.